local_hospital

Kuopio University Hospital

Address
lock Available on a paid plan

Analytical, Diagnostic and Therapeutic Techniques and Equipment – Anesthesia and Analgesia

The pediatric department at Kuopio University Hospital is advancing pain control strategies for children undergoing surgery, testing newer analgesic protocols to reduce opioid exposure and improve recovery.

  • Post‑operative pain management in pediatric surgery
  • Regional anesthesia techniques for adolescents
  • Opioid‑sparing medication regimens

These studies aim to enhance comfort and safety for young patients while supporting faster discharge.

Analytical, Diagnostic and Therapeutic Techniques and Equipment – Diagnosis

Researchers are evaluating cutting‑edge diagnostic tools to enable earlier detection of serious conditions in children, including rapid imaging and biomarker panels.

  • Point‑of‑care ultrasound for abdominal emergencies
  • Multiplex blood tests for infection markers
  • Advanced imaging techniques for tumor staging

Accurate diagnosis supports timely treatment decisions across the hospital’s many therapeutic programs.

Diseases – Bacterial Infections and Mycoses

The site conducts trials on optimal antibiotic use and fungal infection management, seeking to balance efficacy with resistance prevention.

  • Acute otitis media treatment pathways
  • Antibiotic prophylaxis after gynecologic surgery
  • Diagnostic approaches for invasive fungal infections

Findings are expected to refine pediatric antimicrobial stewardship and improve outcomes.

Diseases – Cardiovascular Diseases

Cardiology investigators are testing antiplatelet regimens, blood‑pressure control strategies, and aneurysm‑monitoring protocols to reduce cardiovascular events in young and adult patients.

  • Dual antiplatelet therapy after coronary bypass
  • Home‑based blood pressure monitoring for hypertension
  • Early intervention for unruptured intracranial aneurysms

The goal is to lower rates of heart attacks, strokes, and aneurysm rupture.

Diseases – Digestive System Diseases

Trials focus on inflammatory gut disorders and postoperative recovery, including novel biologics for eosinophilic esophagitis and ulcerative colitis.

  • Tezepelumab for eosinophilic esophagitis
  • Biologic therapy in ulcerative colitis
  • Post‑appendectomy care pathways

These studies aim to improve quality of life and reduce disease‑related complications.

Diseases – Female Urogenital Diseases and Pregnancy Complications

Research includes antibiotic prophylaxis after hysterectomy and immunotherapy for endometrial cancer, seeking safer peri‑operative care and effective adjuvant treatments.

  • Azithromycin versus cefuroxime prophylaxis
  • Checkpoint inhibitor trials in advanced endometrial carcinoma
  • Hormonal therapy safety in reproductive‑age women

Outcomes will guide clinical guidelines for women’s health at Kuopio University Hospital.

Diseases – Hemic and Lymphatic Diseases

The oncology unit leads extensive work on blood‑cancer therapies, evaluating new antibodies and combination regimens for leukemias, lymphomas, and multiple myeloma.

  • Acute myeloid leukemia novel agents
  • Chronic lymphocytic leukemia targeted therapy
  • Diffuse large B‑cell lymphoma immunotherapy
  • Multiple myeloma combination studies

These investigations strive to improve survival and reduce treatment‑related toxicity.

Diseases – Immune System Diseases

Studies address autoimmune and inflammatory conditions, testing cytokine‑targeted drugs to alleviate symptoms and modify disease progression.

  • IL‑33 inhibition for chronic rhinosinusitis with nasal polyps
  • Anti‑IL‑5 therapy in eosinophilic disorders
  • Immune‑modulating agents for pediatric autoimmune disease

Success could expand therapeutic options for patients with refractory immune‑mediated illnesses.

Diseases – Male Urogenital Diseases

Prostate cancer research evaluates hormonal strategies and novel targeted agents to manage both castration‑sensitive and castration‑resistant disease.

  • Advanced metastatic prostate cancer trials
  • Hormone‑resistance reversal therapies
  • Advanced imaging for prostate tumor assessment

Findings aim to extend survival and maintain quality of life for men affected by prostate malignancies.

Diseases – Musculoskeletal Diseases

Investigations target hand contractures, frostbite injuries, and pediatric orthopedic trauma, focusing on functional recovery and scar reduction.

  • Dupuytren's contracture minimally invasive treatment
  • Iloprost versus tPA for severe frostbite
  • Rehabilitation protocols after pediatric fractures

The aim is to restore mobility and reduce long‑term disability.

Diseases – Neoplasms

A comprehensive oncology program tackles solid tumors and hematologic malignancies, testing immunotherapy, targeted agents, and maintenance strategies across cancer types.

  • HER2‑positive early breast cancer adjuvant therapy
  • Non‑small cell lung cancer combination trials
  • High‑risk cutaneous melanoma immunotherapy
  • Ewing sarcoma maintenance regimens
  • Ovarian cancer PARP inhibitor studies

Research strives to increase cure rates and offer personalized treatment options.

Diseases – Nervous System Diseases

Neurology investigators explore seizure control, infantile spasm prevention, and management of chronic subdural hematoma, integrating novel drugs and monitoring technologies.

  • XEN1101 for focal‑onset seizures
  • Vigabatrin prophylaxis for high‑risk infantile spasms
  • Anticoagulation strategies for chronic subdural hematoma
  • Advanced neuroimaging for seizure focus identification

Outcomes aim to reduce seizure frequency and improve neurological recovery.

Diseases – Respiratory Tract Diseases

Respiratory research includes chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and the impact of analgesic administration on breathing patterns.

  • COPD management with inhaled therapies
  • Anti‑fibrotic drug trials for idiopathic pulmonary fibrosis
  • Respiratory monitoring after oxycodone PCA

The goal is to preserve lung function and prevent respiratory complications.

Diseases – Skin and Connective Tissue Diseases

Dermatology studies assess adjuvant immunotherapy for high‑risk melanoma and evaluate treatments for cutaneous lymphomas and connective‑tissue disease biomarkers.

  • Short‑course immunotherapy after melanoma resection
  • Targeted therapy for cutaneous B‑cell lymphoma
  • Biomarker discovery in systemic sclerosis

These projects aim to improve skin cancer outcomes and advance care for rare connective‑tissue disorders.

Not possible to specify

Cross‑disciplinary initiatives integrate imaging innovation, multi‑omics profiling, and patient‑reported outcomes to support diverse therapeutic areas at Kuopio University Hospital.

  • Contrast‑enhanced ultrasound for superficial lymphatic mapping
  • Multi‑omics analyses in hematologic malignancies
  • Digital health tools for real‑time patient monitoring

These efforts enhance precision medicine and streamline trial conduct across the institution.

Site Overview

assignment
87
connected trials
corporate_fare
50
sponsors
science
163
IMPs

Activity Indicator

Last 6 months

6
Trials started
-40% vs previous period.
10
Trials started 6–12 months ago
87
Total trials linked
Highly Active
trending_downDeclining-40%
1
3
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 16 therapeutic areas and 15 of 163 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 143 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
49
Sponsors (total)
50
Active sponsors
31

Sponsor Network

Top 31 by active trials.

lock +30 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +14 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 107 other sites in Finland

description
Trial volume
87
Outperforms 96% of sites
public
Therapeutic diversity
16areas
Outperforms 96% of sites
groups
Sponsor diversity
50sponsors
Outperforms 97% of sites

Therapeutic Area Benchmark — Finland

Select a therapeutic area to compare against other sites in Finland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Finland

Market Share

Country: Finland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Kuopio University Hospital

lock Showing 1 of 87 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticusMarinus Pharmaceuticals Inc.Phase IIINot RecruitingNov 2023Apr 2024

IMP list

lock Showing 1 of 163 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab10Unknown2020-01-302026-07-07

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.